Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletion At 28 ...

The Phase 3 STEER trial enrolled more than 100 children with SMA type 2, ages 2-17, who were able to sit, but hadn't walked ...